-- Guardant Health (GH) 週一宣布，美國食品藥物管理局 (FDA) 已批准其 Guardant360 CDx 檢測作為 Arvinas (ARVN) 和輝瑞 (PFE) 的 Veppanu 的伴隨診斷試劑，用於部分乳癌患者。 該公司表示，這項基於血液的檢測可以識別雌激素受體陽性、HER2 陰性的晚期或轉移性乳癌患者的 ESR1 突變，這些患者在接受過內分泌治療後可能符合 Veppanu 的治療條件。 Guardant Health 表示，這是其第三項獲得 FDA 批准的 ESR1 伴隨診斷試劑，使該檢測獲準的癌症類型總數達到 26 種。
Price: $87.88, Change: $+0.28, Percent Change: +0.32%
The Canadian government tabled its Spring Economic Update (SEU) last week, substantially revising down deficit projections for 2025, with the medium-term outlook slightly improving, said Nomura.Debt-to-GDP projections were also revised modestly lower owing to lower debt levels and a stronger growth profile over the forecast horizon, noted the bank in a note published last week.The government announced the creation of a sovereign wealth fund, with an initial endowment of $25 billion, with more details expected in the coming months.Overall, the SEU suggests Canada's fiscal position remains strong, leaving the government with additional headroom to support the economy if the CUSMA negotiations falter, while allowing the Bank of Canada to remain focused on inflation risks, stated Nomura.The SEU contained few surprises, according to the bank. The government revised down deficit projections for 2025, while the medium-term profile improved slightly.
Electromagnetic Geoservices (EMGS.OL) appointed Glenn Pettersen as interim chief executive after the company completed the sale of its operations and assets to P-2 Riggs Capital in April.The Norwegian geophysical services company on Monday said local law requires the service of a CEO even if the business is no longer actively operating, has no employees, and holds no material assets.
Estee Lauder's (EL) turnaround continues, but headwinds from the Middle East conflict could still weigh on fiscal Q4 results, RBC Capital Markets said in a Monday note.Estee Lauder reported fiscal Q3 adjusted earnings of $0.91 per diluted share, up from $0.65 a year earlier, as net sales increased to $3.71 billion from $3.55 billion. The company also raised its fiscal 2026 adjusted EPS outlook to between $2.35 and $2.45, from $2.05 to $2.25 previously.Business disruptions from the Middle East conflict are estimated to have a negative impact of $0.07 to the company's fiscal 2026 EPS and $0.06 dilutive to fiscal Q4 EPS, the investment firm said. RBC noted that Estee Lauder's updated outlook "assumes no deterioration" in the Middle East beyond May, along with current market conditions.The guidance is still "reasonable" and positions Estee Lauder to hit its targets, RBC added.RBC Capital Markets has an outperform rating and $111 price target on Estee Lauder.Price: $81.35, Change: $+2.05, Percent Change: +2.59%